亞洲知識產權資訊網為知識產權業界提供一個一站式網上交易平台，協助業界發掘知識產權貿易商機，並與環球知識產權業界建立聯繫。無論你是知識產權擁有者正在出售您的知識產權，或是製造商需要購買技術以提高操作效能，又或是知識產權配套服務供應商，你將會從本網站發掘到有用的知識產權貿易資訊。
返回搜索結果

Combination Therapy for Cancer – Oral Fenretinide and Microtubule inhibitors

詳細技術說明
TechSummary:  This inventioncombines fenretinide with microtubule inhibitors to increase thetherapeutic effect of fenretinide as an anti-cancer drug.
*Abstract

Technology Summary: Combines fenretinide with microtubule inhibitors to increase its therapeutic effect as an anti-cancer drug.


Background:  This invention is related to Fenretinide (4-hydroxy(phenyl) retinamide), a synthetic retinoid derivative that has been investigated for potential use in the treatment of cancer and some other diseases, such as macular degeneration.  Specific types of cancer investigated include bladder, breast, Non-Hodgkin's lymphoma, neuroblastoma, and Ewing's sarcoma


Bioavailability of the long-established fenretinide formulation has been a limiting factor in achieving optimal therapeutic benefit.


Technology Description:  This invention proposes the use of fenretinide, a well known anticancer agent, in combination with microtubule inhibitors. These inhibitors are another important class of anti-cancer agents.


Pre-clinical data from multiple tumor xenograft models show that fenretinide is more effective when used with microtubule inhibitors instead of as a single agent.


The combination of fenretinide and microtubule inhibitors is well-tolerated in mice. Its synergistic effect presents a novel treatment approach in oncology.


Kang MH, Wan Z, Kang YH, Sposto R, Reynolds CP (2008). Mechanism of synergy of N-(4-hydroxyphenyl)retinamide and ABT-737 in acute lymphoblastic leukemia cell lines: Mcl-1 inactivation. J Natl Cancer Inst. 2008 Apr 16;100(8):580-95.          


Applications:

  • Cancer treatment
  • Macular degeneration


Advantages: 

  • Orally administered
  • Improved bioavailability
  • Improved anti-tumor activity of fenretinide


Development Stage:  Pre-clinical proof of principle data.


IP Protection: PCT application filed PCT/US2007/011686
*IP Issue Date
May 16, 2007
*IP Type
Other Patent
國家
United States
申請號碼
PCT/US2007/011686
國家/地區
美國

欲了解更多信息，請點擊 這裡
移動設備